84477-85-0

Basic information

• Product Name: 1-N-CBZ-3-METHYL PIPERAZINE
• Synonyms: CHEMPACIFIC 38150;1-N-CBZ-3-METHYL PIPERAZINE;4-N-CBZ-2-METHYL PIPERAZINE;N-1-CBZ-3-METHYL-PIPERAZINE;(R)-1-CBZ-2-METHYL-PIPERAZINE;(R)-1-N-CBZ-2-METHYL-PIPERAZINE;(R)-2-METHYL-PIPERAZINE-1-CARBOXYLIC ACID BENZYL ESTER;(R)-BENZYL 2-METHYLPIPERAZINE-1-CARBOXYLATE
• CAS NO: 84477-85-0
• Molecular Formula: C₁₃H₁₈N₂O₂
• Molecular Weight: 234.29
• Mol File: 84477-85-0.mol
• Article Data: 9

Chemical Properties

• Boiling Point: 358.024 °C at 760 mmHg
• Flash Point: 170.327 °C
• Appearance: /
• Density: 1.106 g/cm³
• Storage Temp.: under inert gas (nitrogen or Argon) at 2–8 °C
• PKA: 8.50±0.40(Predicted)
• CAS DataBase Reference: 1-N-CBZ-3-METHYL PIPERAZINE(CAS DataBase Reference)
• NIST Chemistry Reference: 1-N-CBZ-3-METHYL PIPERAZINE(84477-85-0)
• EPA Substance Registry System: 1-N-CBZ-3-METHYL PIPERAZINE(84477-85-0)

Safety Data

• Hazardous Substances Data: 84477-85-0(Hazardous Substances Data)

Usage

General Description

1-N-CBZ-3-Methyl Piperazine is a chemical compound with the molecular formula C12H18N2O2. It is a white to off-white crystalline powder that is commonly used as an intermediate in the synthesis of pharmaceuticals and agrochemicals. 1-N-CBZ-3-METHYL PIPERAZINE is also known for its use as a chemical building block in organic synthesis and as a reagent in the production of various chemical products. It is important to handle this compound with care as it may cause irritation to the skin, eyes, and respiratory system upon exposure. Additionally, it should be stored in a cool, dry place away from direct sunlight to prevent degradation.

Upstream product

• 109-07-9 (RS)-2-methylpiperazine 
• 501-53-1 benzyl chloroformate 
• 74879-18-8 (S)-2-methylpiperazine 
• 300561-17-5 N-benzyloxycarbonyl-N-(2,3,4,5,6-pentafluorophenyl)methanesulfonamide 
• 215657-34-4 N-benzyloxycarbonyl-N-(2-fluorophenyl)methanesulfonamide 

Downstream Products

• 84477-87-2 H-7 
• 84477-86-1 1-benzyloxycarbonyl-4-(5-isoquinolinesulfonyl)-3-methylpiperazine 

Relevant articles and documents

Design, synthesis and SAR of antitubercular benzylpiperazine ureas

Abstract: N-furfuryl piperazine ureas disclosed by scientists at GSK Tres Cantos were chosen as antimycobacterial hits from a phenotypic whole-cell screen. Bioisosteric replacement of the furan ring in the GSK Tres Cantos molecules with a phenyl ring led to molecule (I) with an MIC of 1?μM against Mtb H37Rv, low cellular toxicity (HepG2 IC50 ~ 80?μM), good DMPK properties and specificity for Mtb. With the aim of delineating the SAR associated with (I), fifty-five analogs were synthesized and screened against Mtb. The SAR suggests that the piperazine ring, benzyl urea and piperonyl moieties are essential signatures of this series. Active compounds in this series are metabolically stable, have low cellular toxicity and are valuable leads for optimization. Molecular docking suggests these molecules occupy the Q0 site of QcrB like Q203. Graphic Abstract: Bioisosteric replacement of N-furfuryl piperazine-1-carboxamides yielded molecule (I) a novel lead with satisfactory PD, metabolism, and toxicity profiles.[Figure not available: see fulltext.]

Microwave-assisted carbamoylation of amines

The influence of microwave irradiation on the reaction of various amines with benzyl chloroformate and di-tert-butyl dicarbonate was investigated. Microwave irradiation was successfully applied to the carbamoylation of several nonfunctionalized and functionalized amines, including amino acids and nucleobases, leading to satisfactory to high product conversion within very short reaction times. Copyright Taylor & Francis Group, LLC.

Cyanophenyl derivative

This application relates to a piperazino-substituted novel cyanophenyl derivative in which a substituted carbamoyl or substituted sulfamoyl group having an aryl, heterocyclic or the like group that may have a substituent group is bonded to one nitrogen atom on the piperazine ring. The compound of this application has an anti-androgen action and is useful in preventing or treating prostatic cancer, benign prostatic hyperplasia and the like diseases.